drugset

drugset / Trial / NCT05814757

OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)

NCT05814757 ↗

Phase 2 Completed 100 enrolled Ocular Therapeutix, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the efficacy and safety of OTX-DED for the short-term treatment of the symptoms of DED

Timeline

Start: 2023-05-11
Primary completion: 2024-05-22
Completion: 2024-05-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dexamethasone	Small molecule	0.3 mg	Other

Indications